Please assess the completion status of the following clinical trial:

Trial Title: Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with hematologically or pathohistologically diagnosed peripheral T/NK-cell lymphoma~* Subjects who have been positive for CCR4~* Subjects who received one or more chemotherapy regimens~* Subjects who relapse after achieving complete response, uncertain complete response or partial response by the last chemotherapy~* Subjects who have an interval of 4 weeks or more between the last day of the prior therapy and the scheduled day of the first KW-0761 treatment~* Subjects with nodal lesions, extranodal lesions and/or cutaneous lesions~* Subjects who have a performance status of 0 to 2~* Subjects who are negative for HBs antigen and reported as not detected for HBV-DNA~* Subjects who are negative for anti-HCV antibody~* Subjects who have normal function of the major organs~* Subjects who have given written voluntary informed consent to participate in the study~Exclusion Criteria:~* Subjects who underwent transplant therapy such as hematopoietic stem-cell transplantation (Subjects who underwent autologous hematopoietic stem-cell transplantation following chemotherapy will not be excluded)~* Subjects who are known carriers of HIV~* Subjects who have active multiple cancer~* Subjects who have a history of allergic reactions to therapeutic antibodies~* Subjects requiring continuous systemic treatment with steroid~* Subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses at enrollment or who may require such radiotherapy after the start of the study~* Subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KW-0761 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).